All In Biotech

Drug Trial Radar · NCT00802373

Solifenacin Succinate Versus Tolterodine 4mg Once Daily

Solifenacin in a Flexible Dose Regimen With Tolterodine as an Active Comparator in a Double-blind, Double-dummy, Randomised Overactive Bladder Symptom Trial

Last checked: Nov 20, 2026Latest source record: Sep 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,355 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,355

Actual

Start

Jul 2003

Primary completion

Oct 2004

Study completion Oct 2004

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Dec 4, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, double-blind, double-dummy, 2-arm, parallel-group, design. Flexible dose regimen for solifenacin succinate, fixed dose treatment regimen for tolterodine. Assessment of OAB symptoms by patient diaries.

Conditions

  • Urinary Bladder, Overactive

Interventions

  • Solifenacin succinateDrug

    oral

  • TolterodineDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in mean number of micturitions per 24 hoursTime frame: Weeks 4, 8 and 12

Locations

95 sites in 17 countries. Site status is shown where the registry gives one.

  • Site not named

    Minsk, Belarus

  • Site not named

    Antwerp, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Middleheim, Belgium

  • Site not named

    Brno, Czechia

  • Site not named

    Bulovce, Czechia

  • Site not named

    České Budějovice, Czechia

  • Site not named

    Mělník, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Aalborg, Denmark

  • Site not named

    Aarhus, Denmark

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Glostrup Municipality, Denmark

  • Site not named

    Herlev, Denmark

  • Site not named

    Kolding, Denmark

  • Site not named

    Odense, Denmark

  • Site not named

    Angers, France

  • Site not named

    Bordeaux, France

  • Site not named

    Clermont-Ferrand, France

  • Site not named

    Lille, France

  • Site not named

    Nantes, France

  • Site not named

    Paris, France

  • Site not named

    Reims, France

  • Site not named

    Rouen, France

  • Site not named

    Saint-Priest-en-Jarez, France

  • Site not named

    Toulouse, France

  • Site not named

    Bad Ems, Germany

  • Site not named

    Emmendingen, Germany

  • Site not named

    Frankfurt, Germany

  • Site not named

    Freiburg im Breisgau, Germany

  • Site not named

    Hagenow, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Koblenz, Germany

  • Site not named

    Rheinfelden, Germany

  • Site not named

    Trier, Germany

  • Site not named

    Uetersen, Germany

  • Site not named

    Athens, Greece

  • Site not named

    Larissa, Greece

  • Site not named

    Pátrai, Greece

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.